Apimeds Pharmaceuticals US, Inc

APUS · NYSE
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Assets
Cash & Equivalents$6,987$8,735$250$3
Short-Term Investments$0$0$0$0
Receivables$0$0$0$0
Inventory$0$0$0$0
Other Curr. Assets$2,099$0$0$10
Total Curr. Assets$9,086$10,350$260$13
Property Plant & Equip (Net)$34$13$0$0
Goodwill$0$0$0$0
Intangibles$0$0$0$0
Long-Term Investments$0$0$0$0
Tax Assets$0$0$0$0
Other NC Assets$130$184$0$0
Total NC Assets$164$197$0$0
Other Assets$0$0$0$0
Total Assets$9,250$10,547$260$13
Liabilities
Payables$0$0$0$0
Short-Term Debt$500$500$624$250
Tax Payable$0$0$0$0
Deferred Revenue$0$0$0$0
Other Curr. Liab.$589$183$287$181
Total Curr. Liab.$1,089$809$1,770$1,024
LT Debt$0$0$250$347
Deferred Rev, NC$0$0$0$0
Deferred Tax Liab, NC$0$0$0$0
Other NC Liab.$0$0$0$0
Total NC Liab.$0$0$250$347
Other Liabilities$0$0$0$0
Cap. Leases$0$0$0$0
Total Liabilities$1,089$809$2,020$1,371
Equity
Pref Stock$0$0$0$0
Common Stock$126$126$79$79
Retained Earnings-$9,238-$7,457-$4,794-$4,392
AOCI$0$0$0$0
Other Equity$17,273$0$0$0
Total Equity$8,161$9,738-$1,761-$1,358
Supplemental Information
Minority Interest$0$0$0$0
Total Liab. & Tot. Equity$9,250$10,547$260$13
Net Debt-$6,487-$8,235$623$593